Semax and Selank Nasal Spray Dual-Peptide Neuroscience Research Guide for UK Laboratories
Among the most actively researched synthetic neuropeptide combinations in contemporary neuroscience, the Semax and Selank blend has attracted significant scientific interest for its complementary mechanisms within central nervous system research models. As UK laboratory interest in intranasal peptide delivery systems continues to grow, this dual-peptide formulation has become a relevant compound for researchers investigating BDNF signalling, GABAergic pathway modulation, neuroplasticity, and stress-cognition interaction models.
At Elevr, we supply Semax/Selank 15mg/15mg a 30mg total high-purity research peptide nasal spray strictly for laboratory and in-vitro research use. This guide is designed to help UK-based researchers understand what each compound is, how they work in research models, and why their combination in a nasal spray delivery format is of scientific interest.
Important Disclaimer: All information in this article relates strictly to laboratory and in-vitro research. Semax/Selank nasal spray supplied by Elevr is intended for research purposes only. It is not approved for human or veterinary use, supplementation, or any therapeutic, diagnostic, or cosmetic application. It has not been evaluated by the MHRA or any regulatory authority for clinical us.
What Is Semax?
Semax is a synthetic heptapeptide derived from the ACTH(4-10) fragment of adrenocorticotropic hormone, studied primarily for its role in BDNF upregulation and neuroprotective signalling in laboratory research models.
Structurally, Semax carries the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and has been the subject of published preclinical and clinical research particularly in models examining cognitive function, neuroprotection, and neurotrophin signalling pathways.
A key research characteristic of Semax is its ability to rapidly upregulate brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in experimental models. Studies involving rodent models have demonstrated that Semax administration may elevate BDNF levels in the hippocampus and frontal cortex regions associated with memory consolidation and cognitive function research. Additionally, Semax has been investigated in cerebral ischaemia models, where published research has examined its relationship with oxidative stress pathways, apoptotic signalling, and neuroinflammatory markers in laboratory systems.
Semax has received regulatory approval in Russia for use in stroke and traumatic brain injury research applications, providing a documented scientific basis for ongoing preclinical investigations globally.
What Is Selank?
Selank is a synthetic heptapeptide analogue of tuftsin a naturally occurring immunomodulatory tetrapeptide studied primarily as a GABAergic anxiolytic and immunomodulatory research compound.
Selank carries the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Like Semax, it was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and has been the subject of published preclinical and clinical research particularly in models examining anxiety-related signalling, GABAergic neurotransmission, and serotonergic modulation.
In laboratory research, Selank is studied as a positive allosteric modulator of GABA-A receptor sensitivity enhancing the receptor's responsiveness to endogenous GABA rather than acting as a direct agonist. This mechanistic profile distinguishes it from classical benzodiazepine compounds in research models, where it has been investigated for anxiolytic-like effects without the sedative characteristics typically associated with direct GABA-A agonists.
Selank has also been examined for its immunomodulatory properties specifically its influence on interferon and cytokine signalling in experimental systems, consistent with its structural relationship to tuftsin, an endogenous immunopeptide produced by IgG cleavage.
Selank received regulatory approval in Russia as an anxiolytic compound, providing a documented research basis for its continued investigation in preclinical laboratory settings worldwide.
What Does 15mg/15mg Mean in a Semax Selank Research Blend?
In Elevr 30mg nasal spray formulation, 15mg/15mg means each active peptide Semax and Selank is present at equal 15mg concentrations within the total 30mg compound volume.
This balanced formulation is designed for research protocols where equal molar representation of both peptides is required for controlled experimental design. Unlike unequal ratio blends, a 15mg/15mg formulation allows researchers to study the combined effect of both compounds without one peptide dominating the experimental signal — an important consideration for reproducible neuroscience research outcomes.
This specific concentration detail is frequently searched by UK researchers and is not clearly explained in most available online resources — making it an important point of transparency for laboratory professionals sourcing this compound.
Why Is Nasal Delivery Studied for Semax and Selank Research?
Intranasal delivery is studied for Semax and Selank because this route allows these peptides to bypass first-pass hepatic metabolism and reach the central nervous system more directly via the olfactory pathway a significant advantage in neuroscience research models.
Both Semax and Selank are heptapeptides with C-terminal Pro-Gly-Pro extensions specifically engineered to improve metabolic stability against rapid proteolytic degradation. Despite this modification, these compounds remain susceptible to hepatic metabolism when delivered via other routes in experimental systems. Intranasal administration allows researchers to study their CNS-related signalling effects with greater bioavailability efficiency in laboratory models.
In preclinical research, the nasal mucosa serves as a direct pathway to the olfactory epithelium and subsequently the CNS making intranasal delivery the most studied administration route for these compounds in neuroscience research protocols. This is reflected in the published literature, where the majority of Semax and Selank research studies have utilised intranasal delivery systems.
How Do Semax and Selank Work Together in Research Models?
Semax and Selank are studied together because they operate through complementary but mechanistically distinct pathways Semax via BDNF/neurotrophin upregulation, Selank via GABAergic modulation allowing researchers to investigate dual-pathway neuroscience models in a single experimental system.
This complementary mechanism is a key reason why the Semax-Selank combination has attracted significant research interest. In practical research terms, the combination addresses a common challenge in stress-cognition research models: anxiety-state suppression of learning paradigms.
Animal models of chronic stress reliably produce BDNF downregulation, hippocampal dendritic atrophy, and impaired long-term potentiation in experimental systems. The Semax-Selank combination has been explored as a research tool for simultaneously attenuating stress marker expression via Selank's GABAergic and serotonergic pathway modulation while supporting neurotrophin signalling via Semax's BDNF pathway activity. This dual mechanism makes the combination particularly relevant for UK researchers investigating stress versus intrinsic cognitive signalling contributions in neuroscience laboratory models.
Key Research Areas Investigated With Semax and Selank
1. BDNF and Neurotrophin Signalling Research
Published research has examined how Semax influences BDNF and NGF expression in rodent hippocampal and cortical models. Studies have reported that Semax may trigger mRNA transcription for neurotrophins within 24 hours of administration in experimental models findings that have made it a relevant tool compound for UK researchers studying neuroplasticity and synaptic strengthening pathways.
2. GABAergic Pathway and Anxiolytic Research Models
Selank's role as a positive allosteric modulator of GABA-A receptors has been examined in multiple preclinical studies. Research has investigated how Selank modulates GABAergic tone in anxiety models without producing the sedative or dependence-related characteristics typically associated with classical benzodiazepine compounds in experimental systems. This mechanistic profile makes Selank a research compound of distinct interest for UK neuroscience laboratories studying anxiety-related signalling.
3. Neuroprotection and Cerebral Ischaemia Research Models
Semax has been studied in cerebral ischaemia models, where published research has examined its relationship with oxidative stress reduction, infarct volume, anti-apoptotic Bcl-2 signalling, and neuroinflammatory marker suppression in laboratory systems. A 2025 study published in Bioinorganic Chemistry and Applications examined Semax's role in reducing reactive oxygen species associated with amyloid-beta/copper interactions a mechanistically distinct neuroprotective pathway that has expanded research interest in this compound beyond classical BDNF studies.
4. Stress-Cognition Interaction Research
The combined Semax-Selank formulation has been explored as a research tool in studies investigating the relationship between stress pathway activation and cognitive signalling endpoints. Researchers studying the confounding variable of anxiety-state suppression in learning paradigms have used this combination to simultaneously address GABAergic tone and neurotrophin availability in controlled experimental systems.
5. Immunomodulatory Research Models
Selank's structural relationship to tuftsin an endogenous immunopeptide has led to research examining its influence on interferon and cytokine signalling in experimental models. This immunomodulatory research dimension is distinct from its GABAergic properties and represents an additional area of scientific interest for UK researchers working at the interface of neuroimmunology and peptide biology.
What Is the Difference Between Semax and Selank in a Research Formulation?
This is one of the most frequently searched questions by UK researchers, and one that most online sources answer incompletely.
The key distinction in a research context:
- Semax (ACTH-derived) → studied for BDNF/NGF upregulation, dopaminergic/serotonergic modulation, neuroprotection, cognitive activation in research models
- Selank (tuftsin-derived) → studied for GABA-A positive allosteric modulation, serotonergic stabilisation, anxiolytic-like effects, immunomodulation in research models
The critical research distinction: Semax is characterised as an activating neurotrophin compound in research models, while Selank is characterised as a calming GABAergic modulator. Their combination allows researchers to study both pathways simultaneously in a single experimental system something neither compound alone provides.
Elevr Semax/Selank 15mg/15mg 30mg Nasal Spray: Research Compound Specification
Elevr Semax/Selank nasal spray is formulated specifically for laboratory and research use, meeting the quality standards required for reproducible neuroscience research:
- Total peptide content: 30mg (Semax 15mg + Selank 15mg)
- Purity: ≥99% verified via HPLC analysis
- Format: Sterile nasal spray solution in metered-dose delivery system
- Carrier: Sterile aqueous research-grade solution
- Certificate of Analysis (COA): Batch-specific, available on request
- Storage: Refrigerated at 2°C to 8°C, protected from light
- Labelling: Strictly for laboratory research use only
- Delivery: Fast, discreet UK dispatch with secure packaging
Whether you are investigating dual-pathway neuroscience models, BDNF signalling research, GABAergic modulation, or stress-cognition interaction paradigms, Elevr Semax/Selank blend provides a reliable, fully documented research compound for UK laboratory use.
View Elevr Semax/Selank 30mg Nasal Spray Research Compound
Frequently Asked Questions
Q: What is Semax Selank nasal spray used for in research?
Semax/Selank nasal spray is studied in neuroscience laboratory research for its dual-pathway activity Semax for BDNF neurotrophin upregulation and neuroprotection research, Selank for GABAergic pathway modulation and anxiolytic-related signalling studies. The nasal spray format is specifically chosen in research protocols to study intranasal delivery of these peptides to CNS-related experimental models.
Q: What does 15mg/15mg mean in a Semax Selank blend?
In a 15mg/15mg formulation, each peptide Semax and Selank is present at an equal 15mg concentration within the total 30mg compound volume. This balanced ratio is used in research protocols requiring equal molar representation of both compounds for controlled experimental design and reproducible outcomes.
Q: Why is Semax studied in neuroprotection research?
Semax is studied in neuroprotection research because published preclinical investigations have examined its role in BDNF upregulation, reduction of oxidative stress markers, suppression of neuroinflammatory signalling, and anti-apoptotic pathway activity in cerebral ischaemia laboratory models. It has received regulatory approval in Russia for stroke-related research applications.
Q: How does Selank differ from benzodiazepines in GABAergic research?
In laboratory research models, Selank acts as a positive allosteric modulator of GABA-A receptors enhancing the receptor's sensitivity to endogenous GABA rather than acting as a direct agonist, unlike classical benzodiazepines. This mechanistic distinction is the basis for research interest in Selank as a GABAergic compound without classical benzodiazepine-associated sedative characteristics in experimental systems.
Q: Why are Semax and Selank studied together in research?
Semax and Selank are studied together because their distinct mechanisms BDNF upregulation (Semax) and GABAergic modulation (Selank) are complementary in research models. This combination allows researchers to investigate dual-pathway neuroscience paradigms, particularly in stress-cognition interaction studies where both neurotrophin support and anxiety-pathway modulation are relevant experimental variables.
Q: Is Elevr Semax Selank nasal spray suitable for human use?
No. Elevr Semax/Selank 30mg nasal spray is supplied strictly for laboratory and research use only. It is not intended for human or veterinary use, supplementation, or any therapeutic, diagnostic, or cosmetic application. It has not been evaluated by the MHRA or any regulatory authority for clinical use.
